Taglich Brothers Initiates Coverage on OxySure Systems, Inc.
OxySure Systems, Inc . (OTCQB: OXYS), based in Frisco, Texas, manufactures and markets the FDA-approved OxySure Model 615, a low cost, lightweight portable catalytic oxygen generator for medical emergency use. Oxysure's technology offers lifesaving potential in cases of major adverse cardiac events, severe trauma, and respiratory distress.
The company's technology rapidly generates medically pure oxygen by combining two inert powders, obviating the need for storage in compressed tanks or other oxygen generators that pose explosion or fire hazards.
The OxySure Model 615 can be prepositioned in educational institutions, manufacturing facilities, commercial and government office buildings, sports stadia, restaurants, airports, military installations and a wide variety of other public venues for emergency administration of acute oxygen therapy by untrained non-medical persons. Broad emergency application potential prior to arrival of first responders or admission to a medical treatment facility underlies the appeal of the Model 615.
The OxySure (OXYS.OB) 615 is sold through more than 40 independent commission agents in the US and overseas distributors in Australia and New Zealand, the UK, Brazil, South Africa and Turkey.
OXYS also distributes automatic external defibrillators, more than two million of which are in service worldwide for the treatment of cardiac arrest victims before the arrival of first responders. The company's model 615 generator is an ideal companion medical device that can rapidly administer the oxygen needed to resuscitate patients who suffer unexpected major adverse cardiac events.
The complete 15-page report is available at www.taglichbrothers.com.
We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the company mentioned in this report.
All research issued by Taglich Brothers, Inc. is based on public information. All research issued by Taglich Brothers, Inc. is based on public information. In June 2013 the company paid an initial monetary engagement fee of US$4,500 to Taglich Brothers, Inc. representing payment for the first three months of the creation and dissemination of research reports, after which the company will pay Taglich Brothers, Inc. a monetary fee of US$1,500 per month for such services.
For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.
Contact: Richard Oh Taglich Brothers, Inc. 631-757-1500
Source: OxySure Systems, Inc.